Table 2.
Response | ||
CR (incl. CRu) | 17/30 (57%) | |
PR | 5/30 (17%) | |
Disease status | ||
Relapsed CR | 16/26 (62%) | |
Primary refractory | 1/4 (25%) | |
Survival (median follow up; 19 months) | ||
Overall survival (2 years) | 45.2% | |
Progression‐free survival (2 years) | 37.2% |